| __timestamp | AstraZeneca PLC | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 18516000 |
| Thursday, January 1, 2015 | 5997000000 | 34140000 |
| Friday, January 1, 2016 | 5890000000 | 51872000 |
| Sunday, January 1, 2017 | 5757000000 | 71772000 |
| Monday, January 1, 2018 | 5932000000 | 97501000 |
| Tuesday, January 1, 2019 | 5958000000 | 118590000 |
| Wednesday, January 1, 2020 | 5991000000 | 169802000 |
| Friday, January 1, 2021 | 9736000000 | 192507000 |
| Saturday, January 1, 2022 | 9762000000 | 199563000 |
| Sunday, January 1, 2023 | 10935000000 | 253598000 |
| Monday, January 1, 2024 | 13583000000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, innovation is key. Over the past decade, AstraZeneca PLC has consistently outpaced Xencor, Inc. in research and development (R&D) spending. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, reaching a peak of approximately $10.9 billion in 2023. In contrast, Xencor's investment grew by a remarkable 1,270%, yet it only reached around $254 million in the same year. This stark difference highlights AstraZeneca's commitment to innovation, investing over 40 times more than Xencor in 2023 alone. Such financial dedication underscores AstraZeneca's strategic focus on pioneering new treatments and maintaining its competitive edge in the global market. As the pharmaceutical landscape evolves, these investments could be pivotal in shaping the future of healthcare.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Alpine Immune Sciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Arrowhead Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Xencor, Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Xencor, Inc. Allocate Funds
R&D Insights: How GSK plc and Xencor, Inc. Allocate Funds
Research and Development Investment: argenx SE vs Xencor, Inc.
Insmed Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Veracyte, Inc. vs Xencor, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Xencor, Inc.
R&D Spending Showdown: Protagonist Therapeutics, Inc. vs Xencor, Inc.
R&D Insights: How Celldex Therapeutics, Inc. and Xencor, Inc. Allocate Funds